High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD
Indiana University
Indiana University
M.D. Anderson Cancer Center
University of Nebraska
Rhizen Pharmaceuticals SA
Alliance for Clinical Trials in Oncology
M.D. Anderson Cancer Center